CTOs on the Move

GreenSky

www.greensky.com

 
The GreenSky Loan Program offers fast, easy online loans to help you live better. Improve your home, fix your smile, get in shape. GreenSky gets you there faster.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
Gabe Crowson
VP - Product Counsel, Originations Profile

Similar Companies

Sitebrand

Sitebrand Inc. is a Gatineau, QC-based company in the Software and Internet sector.

Haiku

Haiku, Inc. is a non-profit organization that supports the Haiku Project and the development of the Haiku operating system and its online community.

GCommerce

GCommerce Inc. is a Des Moines, IA-based company in the Software and Internet sector.

Data Conversion Laboratory

Data Conversion Laboratory is a leader in organizing, converting, and moving content to modern formats for wide access and new revenue streams. With expertise across many industries, DCLs proprietary technology matched with US-based project management teams solve clients complex conversion challenges securely, accurately and on-time. Serving businesses, government, nonprofits and individuals by future-proofing their content, DCL started in 1981 and has been named as one of the Top 100 Companies in the Digital Content Industry: The 2012-2013 EContent 100, for the second year running.

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.